https://academic.oup.com/eurheartj/article/45/41/4414/7744246?login=false
.
The SUCCOUR-MRI trial demonstrated that approximately one-third of patients deemed at risk of CTRCD developed an isolated reduction in GLS. A cardioprotection strategy based on the renin–angiotensin system and beta-adrenoceptor inhibition resulted in better preservation of 12-month MRI-LVEF compared with usual care.
.
Sim, faz diferença para o paciente em quimioterapia, ser acompanhado por análise da Deformação GLS.
.
Já temos documentação para uso e ressarcimento!
.